News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,981 Results
Type
Article (14903)
Company Profile (299)
Press Release (266773)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79948)
Career Advice (163)
Deals (13363)
Drug Delivery (39)
Drug Development (50720)
Employer Resources (31)
FDA (5850)
Job Trends (5180)
News (145251)
Policy (10085)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21794)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6044)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4571)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3132)
Cardiovascular disease (237)
Career advice (148)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43693)
Collaboration (1148)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4325)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (214)
Earnings (31695)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51728)
Executive appointments (622)
FDA (7598)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6622)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7362)
IRA (12)
Job creations (870)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (244)
Leadership (9)
Legal (1403)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6630)
Metabolic disorders (724)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1950)
Neurotech (1)
NextGen: Class of 2026 (2035)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (329)
Peanut (43)
People (26675)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15479)
Phase 2 (20298)
Phase 3 (12835)
Pipeline (3251)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1450)
Recruiting (12)
Regulatory (9904)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2008)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (13)
Last 7 days (340)
Last 30 days (1127)
Last 365 days (17821)
2026 (1664)
2025 (18112)
2024 (20559)
2023 (22420)
2022 (26828)
2021 (27812)
2020 (23368)
2019 (16251)
2018 (11766)
2017 (13766)
2016 (11869)
2015 (14370)
2014 (10402)
2013 (7518)
2012 (7582)
2011 (7670)
2010 (7459)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18271)
Australia (3111)
California (7086)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (240)
Europe (39173)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5583)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1646)
New Mexico (13)
New York (1762)
North Carolina (827)
North Dakota (6)
Northern California (3479)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2811)
Tennessee (40)
Texas (909)
United States (23352)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,981 Results for "denali therapeutics inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals
Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 for Pompe disease.
December 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
February 2, 2026
·
1 min read
Press Releases
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 5, 2026
·
15 min read
Press Releases
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
·
3 min read
Press Releases
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
January 30, 2026
·
8 min read
Press Releases
Denali Therapeutics Announces Board and Executive Leadership Updates
November 6, 2025
·
7 min read
Press Releases
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 4, 2025
·
8 min read
Press Releases
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
·
4 min read
Press Releases
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 6, 2026
·
10 min read
Rare diseases
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which is awaiting an FDA decision on or before Feb. 8.
January 28, 2026
·
2 min read
·
Dan Samorodnitsky
1 of 28,199
Next
